Types of Childhood Cancer: How Each One Works and When It Is Used

A five-year-old with bruises on her shins is not news. A five-year-old with bruises on her back, a three-week fever that never quite breaks and a pallor her grandmother notices before her parents do is a different story, and it is the kind of story pediatricians are trained to hear in the background noise of ordinary childhood.

Cancer in children is rare. In the United States, roughly 15,000 people under 20 are diagnosed each year, a small fraction of the nearly two million adult diagnoses (NIH/NCI). Yet it remains the leading cause of death by disease past infancy, which is exactly why families who face it deserve clear information rather than either reassurance or alarm.

This guide walks through the major types, how each one starts at the cellular level, the ages at which each tends to appear, and how clinicians decide which treatment approach fits which disease. Where the evidence is strong, we say so. Where it is uncertain, we say that too.

Why childhood cancer is not simply adult cancer in a smaller body

Adult cancers are mostly carcinomas, tumors of the lining tissues in the lung, breast, colon and prostate that accumulate decades of damage from smoking, sun, diet and time. Children have not lived long enough for that kind of wear. Their cancers arise instead from cells that were still developing: blood-forming cells in the marrow, immature nerve cells, the primitive tissue that builds a kidney or an eye in the womb.

That difference matters in three practical ways. First, childhood cancers are rarely linked to lifestyle, so there is nothing a parent did or failed to do that caused them. Second, they tend to grow fast, which sounds frightening but has an upside: rapidly dividing cells are often more sensitive to chemotherapy and radiation than slow-growing adult tumors. Third, because the tissues involved are still maturing, treatment has to weigh cure against long-term effects on growth, learning, fertility and heart function in a way adult oncology usually does not.

The World Health Organization estimates that about 400,000 children and adolescents aged 0 to 19 develop cancer each year worldwide, and that in high-income countries more than 80 percent are cured, compared with fewer than 30 percent in many low- and middle-income countries (WHO). The gap is not biology. It is access to diagnosis, supportive care and completed treatment.

What are the 12 types of childhood cancer?

When people search for “the 12 types,” they are usually reaching for the International Classification of Childhood Cancer, the system epidemiologists use to sort pediatric tumors by the tissue they come from rather than the organ where they sit. The 12 diagnostic groups, with their approximate share of US diagnoses in children under 15, are shown below. Shares are rounded and drawn from NIH/NCI surveillance data; they shift somewhat when adolescents are included.

Group	Type	Approx. share (0–14 yrs)	Typical age at diagnosis
I	Leukemias	~28%	2–5 (ALL); any age (AML)
II	Lymphomas	~8%	Older children and teens
III	Brain and spinal cord tumors	~26%	Any age; peak under 10
IV	Neuroblastoma and other nerve-cell tumors	~6%	Under 5, often under 2
V	Retinoblastoma	~2%	Under 5, often under 2
VI	Kidney tumors (mainly Wilms)	~5%	3–4
VII	Liver tumors	~1–2%	Under 3 (hepatoblastoma)
VIII	Bone tumors	~3%	Teens
IX	Soft-tissue sarcomas	~7%	Under 10 (rhabdomyosarcoma); teens (others)
X	Germ cell tumors	~3%	Infancy and adolescence
XI	Other epithelial tumors and melanoma	~4%	Mostly teens
XII	Other and unspecified	<1%	Varies

Two groups, leukemias and brain tumors, account for more than half of all cases. The remaining ten are individually rare, which is why a general pediatrician may see only a handful of childhood cancers across a whole career, and why specialist centers pool their experience through cooperative trial groups.

What is the most common cancer in childhood?

Leukemia, and specifically acute lymphoblastic leukemia (ALL), which makes up about three of every four childhood leukemias (NIH/NCI). Leukemias together account for roughly 28 percent of cancers in children under 15, edging out brain and spinal cord tumors, which sit just behind at about 26 percent. Once you include teenagers, brain tumors, lymphomas and thyroid cancer gain ground, and the picture starts to look a little more like young-adult oncology.

The age curve for ALL is unusually sharp. Incidence peaks between ages two and five, then falls, then rises again slowly in adolescence and across adulthood. Researchers have long suspected that this early peak reflects something about how the infant immune system develops, but the mechanism remains unproven, and the honest summary is that most cases have no identifiable cause.

Leukemia is also the type most families have heard of, which shapes how symptoms are interpreted. A child with unexplained bruising gets a blood test quickly. A child with morning headaches and a slight change in handwriting, a classic brain-tumor presentation, may see several clinicians before anyone orders imaging. Awareness of the second most common group deserves to catch up with the first.

How leukemia works: acute lymphoblastic versus acute myeloid

Bone marrow is a factory. Stem cells there divide and mature along two production lines: the lymphoid line, which produces the B and T cells of the immune system, and the myeloid line, which produces red cells, platelets and the infection-fighting neutrophils. Leukemia is what happens when a cell on one of those lines acquires a genetic error that lets it multiply without maturing. The marrow fills with useless immature cells called blasts, and the useful products dwindle.

That crowding explains the symptoms. Too few red cells causes pallor and fatigue. Too few platelets causes bruising, nosebleeds and pinpoint red spots called petechiae. Too few working white cells causes fevers and infections that keep coming back. Blasts spilling into the bloodstream can settle in the liver, spleen and lymph nodes, enlarging them, and can reach the fluid around the brain.

ALL arises from the lymphoid line and has the early-childhood peak described above. Acute myeloid leukemia (AML) arises from the myeloid line, is roughly a quarter as common in children, appears at any age, and is generally treated with shorter but more intensive chemotherapy. ALL treatment, by contrast, typically runs about two to three years, with an intense first phase to clear the marrow followed by a long, lower-intensity maintenance phase to prevent relapse (NHS; Mayo Clinic). Chronic leukemias, common in adults, are rare in children.

Brain and spinal cord tumors in children

Brain tumors are the most common solid tumors in children and the leading cause of cancer death in this age group (NIH/NCI). The word “tumor” covers very different diseases here. Some are low-grade gliomas that grow over years and may be cured by surgery alone. Others, such as medulloblastoma, are fast-growing and require surgery, radiation and chemotherapy. A few, including tumors that grow diffusely through the brainstem, remain very difficult to treat despite decades of research, and clinicians are frank with families about that.

Where a tumor sits determines what it does. Growths in the cerebellum, at the back of the skull, cause unsteadiness and clumsiness. Tumors that block the flow of cerebrospinal fluid raise pressure inside the skull, producing the headache that is worst on waking and often accompanied by vomiting, which is typically not preceded by nausea. Brainstem tumors can affect eye movements, facial symmetry and swallowing. Very young children, whose skull bones have not fused, may simply show a rapidly enlarging head circumference.

Treatment planning here is more constrained than anywhere else in pediatric oncology, because the organ being treated is the one doing the growing and learning. Radiation to a young brain is used sparingly and delayed where possible, and surgeons weigh how much tumor to remove against the function of the tissue around it. Modern classification increasingly relies on molecular profiling rather than microscope appearance alone, which has reshaped how several tumor types are grouped and treated.

Hodgkin and non-Hodgkin lymphoma: cancers of the immune system

Lymphoma and leukemia are cousins. Both come from lymphoid cells, but leukemia lives mainly in the marrow and blood while lymphoma forms solid masses in lymph nodes, the spleen, the thymus behind the breastbone, or the gut wall. The boundary is somewhat arbitrary; a lymphoblastic lymphoma with heavy marrow involvement is essentially ALL by another name.

Hodgkin lymphoma is defined by a particular abnormal cell, the Reed-Sternberg cell, surrounded by a crowd of normal immune cells reacting to it. It is a disease of adolescents and young adults far more than of small children, and it usually presents as a painless rubbery lump in the neck or above the collarbone. Some patients also have drenching night sweats, unexplained weight loss or persistent fevers, the so-called B symptoms that influence staging.

Non-Hodgkin lymphomas in children are mostly aggressive, fast-growing types such as Burkitt lymphoma, which can double in size within a day or two and often appears in the abdomen, causing pain, swelling or a sudden bowel blockage. That speed is alarming, but it also makes these tumors highly responsive to chemotherapy. Childhood Hodgkin lymphoma has among the highest survival rates of any cancer at any age, exceeding 95 percent at five years in US data (NIH/NCI), and current research is largely about achieving the same result with less radiation and fewer long-term side effects.

Neuroblastoma and retinoblastoma: tumors left over from the womb

Some childhood cancers are best understood as development that failed to finish. During fetal life, clusters of primitive cells are supposed to mature into adrenal glands, sympathetic nerves and the light-sensing retina. When a cluster keeps dividing instead, the result is an embryonal tumor, and these are almost exclusively diseases of babies and preschoolers.

Neuroblastoma arises from immature nerve cells, most often in the adrenal gland on top of the kidney, though it can appear anywhere along the sympathetic chain from neck to pelvis. It is the most common cancer diagnosed in the first year of life (NIH/NCI). Its behavior spans an extraordinary range. Some infant tumors shrink and disappear on their own, and clinicians deliberately watch rather than treat them. High-risk disease in older children, often marked by a gene amplification called MYCN, spreads to bone and marrow and requires the most intensive multimodal treatment in pediatric oncology, including immunotherapy that targets a molecule on the tumor surface.

Retinoblastoma begins in the retina and is often first noticed in a photograph: one pupil reflects white instead of red in the camera flash. A newly turned-in or wandering eye is the other common sign. About 40 percent of cases are hereditary, linked to an inherited change in the RB1 gene, and these children tend to be diagnosed younger and to have tumors in both eyes (NIH/NCI). Survival in high-income countries exceeds 95 percent; the modern goal is saving vision as well as life, using focal treatments such as laser and freezing whenever the tumor is small enough.

Wilms tumor and liver cancers in young children

Wilms tumor, also called nephroblastoma, is the classic childhood kidney cancer and one of the field’s great success stories. It arises from leftover embryonic kidney tissue, usually appears between ages three and four, and most often announces itself as a firm, smooth swelling in a toddler’s belly that a parent feels while bathing or dressing the child. Some children have blood in the urine, high blood pressure or abdominal pain, but many feel entirely well.

A small share of Wilms cases occur alongside congenital conditions such as aniridia (absence of the iris), overgrowth syndromes or genital abnormalities, and children with those conditions are offered regular ultrasound screening in early childhood. For the majority without a syndrome, there is no known cause and no screening.

Treatment relies on surgery to remove the affected kidney, combined with chemotherapy and, for more advanced stages or less favorable microscopic features, radiation. Five-year survival for favorable-histology Wilms tumor is around 90 percent (NIH/NCI), and much of the current research focuses on identifying children who can safely receive less treatment.

Liver cancers are rarer. Hepatoblastoma affects children under three and is more common in babies born prematurely or with very low birth weight. Hepatocellular carcinoma, the adult liver cancer, occasionally appears in older children, sometimes on a background of chronic hepatitis B or an inherited liver disease. Both are usually managed with chemotherapy to shrink the tumor followed by surgery, and liver transplantation is an option when the tumor cannot otherwise be removed.

Bone tumors and soft-tissue sarcomas: the cancers of growth spurts

Sarcomas are cancers of the body’s structural tissues: bone, muscle, cartilage, fat and the fibrous tissue that holds everything together. In children they follow two age patterns that tell you something about their biology.

Osteosarcoma and Ewing sarcoma, the two main bone cancers, cluster in adolescence, and osteosarcoma in particular favors the fastest-growing parts of the fastest-growing bones: around the knee and shoulder, during the teenage growth spurt. The most common first symptom is bone pain, often worse at night or with activity, which is easily attributed to sports or growing pains. Persistent pain in one spot, a swelling over the bone, or a fracture from a minor knock should prompt an X-ray. Ewing sarcoma can also arise in the pelvis, ribs or spine and sometimes in soft tissue rather than bone.

Rhabdomyosarcoma, the most common soft-tissue sarcoma in children, comes from cells that were meant to become skeletal muscle and appears mostly in children under ten. It can grow almost anywhere, including the head and neck, the bladder and reproductive organs, and the limbs, so its symptoms depend entirely on location: a bulging eye, a nasal blockage, difficulty passing urine, a painless lump in an arm.

Bone sarcomas are treated with chemotherapy before and after surgery, and limb-sparing operations have replaced amputation in most cases. Five-year survival for localized osteosarcoma is about 70 percent, falling sharply when the cancer has spread to the lungs at diagnosis (NIH/NCI). That gap has not narrowed much in three decades, and it remains one of the most pressing unmet needs in pediatric oncology.

Germ cell tumors and the rare types clinicians see once a decade

Germ cells are the ancestors of eggs and sperm. Early in fetal life they migrate from the yolk sac toward the developing gonads, and a few can stray and lodge along the midline of the body. Tumors that grow from them therefore appear in the ovaries and testes but also in the tailbone region of newborns, the chest, and the pineal region of the brain. The two age peaks, infancy and adolescence, reflect that developmental history. Many germ cell tumors release measurable proteins into the blood, which helps with diagnosis and lets clinicians track response to treatment without repeated scans.

Beyond these, a long tail of rare cancers exists. Thyroid cancer is the most common carcinoma in teenagers and carries a very high survival rate. Melanoma occasionally occurs in children, more often in those with very fair skin or many moles. Nasopharyngeal carcinoma, adrenocortical tumors, pancreatic tumors and others each account for a few dozen US diagnoses a year (NIH/NCI).

Rarity has consequences. Symptoms may be misattributed for longer, and treatment protocols are often borrowed from adult medicine and adapted rather than built from pediatric trial data. For families facing one of these diagnoses, referral to a center that participates in cooperative research groups and international registries genuinely matters, because it is the only way experience with a disease seen a few times a year accumulates into knowledge.

How treatment is matched to the type: what is used and when

There is no single treatment for childhood cancer. Instead, a small number of tools are combined in proportions dictated by the diagnosis, its subtype, how far it has spread and increasingly by the genetic changes inside the tumor cells.

• Chemotherapy uses medicines that damage rapidly dividing cells. It is the backbone of leukemia and lymphoma treatment, because those cancers are spread throughout the blood and marrow from the start, and it is used before surgery to shrink most solid tumors.
• Surgery is the main curative step for many solid tumors, including Wilms tumor, low-grade brain tumors, bone sarcomas and germ cell tumors. It has essentially no role in leukemia.
• Radiation therapy targets a defined area with high-energy beams. It is central for some brain tumors and used selectively for lymphoma, sarcoma and high-risk neuroblastoma. Because it can affect growing tissue for decades, it is avoided or delayed in the youngest children where the evidence allows.
• Stem cell transplant lets clinicians give very high-dose chemotherapy and then rescue the marrow with the child’s own or a donor’s stem cells. It is reserved for high-risk or relapsed leukemia and high-risk neuroblastoma.
• Immunotherapy and targeted therapy harness the immune system or block specific molecular switches. Cell-based immunotherapy is now part of care for some relapsed ALL, and antibody treatment is standard for high-risk neuroblastoma.

Risk stratification is the organizing idea. A child with standard-risk ALL and a child with high-risk ALL receive protocols of very different intensity, and the assignment depends on age, initial white cell count, specific chromosomal changes and how quickly the marrow clears in the first weeks. All treatment decisions rest with the child’s oncology team, and most children in high-income countries are treated within clinical trial protocols that refine these choices over time.

What is the most curable childhood cancer? Survival, stated honestly

Overall, about 85 percent of US children diagnosed with cancer are alive five years later, up from roughly 58 percent in the mid-1970s (NIH/NCI). That average hides enormous variation, and the variation is what families actually need to know.

At the top of the range sit several diseases whose five-year survival exceeds 90 percent: childhood Hodgkin lymphoma, retinoblastoma, standard-risk ALL, favorable-histology Wilms tumor, most germ cell tumors and thyroid carcinoma. Which is “most curable” depends on how you count; Hodgkin lymphoma and retinoblastoma are usually cited, but the honest answer is that a handful of types are now so reliably treatable that research has shifted toward reducing treatment rather than adding it.

In the middle are cancers where outcome depends heavily on stage and biology: neuroblastoma, rhabdomyosarcoma, AML, and osteosarcoma and Ewing sarcoma, where localized disease does well and metastatic disease does not.

At the bottom are a few tumors, mostly in the brain, for which no reliably curative treatment exists. Clinicians do not hide this from families, and neither should an article about childhood cancer.

Two cautions about all of these figures. Five-year survival is a population statistic, not a forecast for an individual child, whose outlook is shaped by dozens of factors a summary number cannot hold. And the figures describe children diagnosed years ago; treatment has changed since, usually for the better.

What is the life expectancy of childhood leukemia survivors?

Most children treated for ALL today are expected to live long lives, and the majority of adult survivors are working, studying, raising families and doing the ordinary things their peers do. That is the headline, and it is supported by decades of follow-up.

The fine print is that survival and full health are not the same thing. Long-term cohort studies following tens of thousands of survivors have found that a majority develop at least one chronic health condition by middle adulthood, and that survivors as a group have higher rates of heart disease, second cancers, hormonal problems and reduced fertility than siblings who never had cancer (NIH/NCI Late Effects summary). Radiation to the brain in early childhood, used far less now than in the 1980s, is linked to learning difficulties and hormone deficiencies. Certain chemotherapy classes can weaken the heart muscle years later.

Life expectancy for survivors as a group is somewhat shorter than for the general population, largely because of these late effects, but the gap has narrowed for children treated in more recent decades as protocols have removed or reduced the most damaging elements. Individual life expectancy depends heavily on which treatments a child received, at what age, and on lifestyle and follow-up afterward.

The practical response is lifelong survivorship care. Most pediatric oncology programs give families a treatment summary and a follow-up plan specifying which screening tests are recommended and how often, so that problems such as early heart changes or thyroid dysfunction are found while they are manageable.

Warning signs and when to see a doctor

The symptoms of childhood cancer are, almost without exception, also the symptoms of common minor illnesses. Fatigue, fever, bruises, headaches, limping and stomach aches fill every pediatric waiting room, and the overwhelming majority have benign explanations. What distinguishes the rare serious case is usually persistence, progression or an unusual combination.

Contact your child’s doctor promptly for any of the following:

• A fever lasting more than a week without a clear source, or infections that keep recurring
• Unexplained pallor and tiredness that does not improve with rest
• Bruising in unusual places such as the back or chest, frequent nosebleeds, or a rash of tiny red dots
• A lump or swelling anywhere, especially one that is painless, firm and growing, or a swollen belly
• Headaches that are worst on waking, particularly with vomiting, or new problems with balance, vision or coordination
• Bone or joint pain in one spot that persists for more than a few weeks, wakes the child at night, or is not explained by an injury
• A white reflection in one pupil in photographs, or an eye that has newly turned inward or outward
• Unexplained weight loss, drenching night sweats, or a change in behavior or school performance without obvious cause

Seek same-day or emergency care for a child who is difficult to rouse, has a severe headache with repeated vomiting, develops sudden weakness or a seizure, is breathing with difficulty, or has bleeding that will not stop. None of these signs means cancer. Each means a child should be examined rather than watched.

What causes childhood cancer? Separating evidence from guilt

Parents of a newly diagnosed child almost always ask what they did wrong. The evidence-based answer is: nothing. Unlike adult cancers, most childhood cancers are not linked to diet, environment, household products, cell phones or anything else within a family’s control (MedlinePlus; NIH/NCI). They appear to arise from random genetic errors during the rapid cell division of early development.

A minority of cases, on the order of 8 to 10 percent in large sequencing studies, involve an inherited genetic predisposition (NIH/NCI). Examples include the RB1 gene in retinoblastoma, Li-Fraumeni syndrome, neurofibromatosis, and conditions such as Down syndrome, which raises leukemia risk. Children with these conditions may be offered surveillance, and genetic counseling is increasingly part of pediatric oncology care.

A few external factors are established. High-dose ionizing radiation, such as from radiotherapy for a previous cancer, increases risk. Some chemotherapy drugs used for a first cancer raise the chance of a second. Chronic hepatitis B infection is linked to liver cancer in some regions, and Epstein-Barr virus contributes to certain lymphomas. Beyond these, studies of pesticides, air pollution, power lines and parental smoking have produced inconsistent or small associations that do not support confident conclusions, and mainstream health agencies describe them as unproven.

That uncertainty is frustrating, but it also means the search for blame is not only painful but unfounded. The energy is better spent on early recognition, complete treatment and long-term follow-up, which are the three things the evidence actually shows change outcomes.

Frequently asked questions

What are the 12 types of childhood cancer?

The 12 groups of the International Classification of Childhood Cancer are leukemias, lymphomas, brain and spinal cord tumors, neuroblastoma and other nerve-cell tumors, retinoblastoma, kidney tumors, liver tumors, bone tumors, soft-tissue sarcomas, germ cell tumors, other epithelial tumors including melanoma and thyroid cancer, and a final category of rare or unspecified cancers. The system groups tumors by the tissue they arise from rather than the organ where they are found.

What is the most common cancer in childhood?

Leukemia is the most common childhood cancer, accounting for about 28 percent of cancers in children under 15, and acute lymphoblastic leukemia makes up about three-quarters of those cases. Brain and spinal cord tumors are close behind at roughly 26 percent and are the most common solid tumors. Among teenagers, lymphomas and thyroid cancer become more prominent.

What is the most curable childhood cancer?

Childhood Hodgkin lymphoma and retinoblastoma are usually cited, each with five-year survival above 95 percent in US data, though standard-risk acute lymphoblastic leukemia, favorable Wilms tumor, most germ cell tumors and thyroid cancer are also above 90 percent. Survival statistics describe groups of children diagnosed years ago, not an individual child’s outlook, which depends on subtype, stage and biology.

What is the life expectancy of childhood leukemia survivors?

Most children treated for leukemia today are expected to live long lives, but long-term studies show survivors have higher rates of heart disease, second cancers and hormonal problems than their siblings, and a somewhat shorter average life expectancy as a group. That gap has narrowed for children treated with more recent, less intensive protocols. Lifelong survivorship follow-up is recommended so late effects are found early.

What is the difference between leukemia and lymphoma in children?

Both come from lymphoid immune cells, but leukemia lives mainly in the bone marrow and blood, causing anemia, bruising and infections, while lymphoma forms solid masses in lymph nodes, the chest, the spleen or the gut. The line between them is partly arbitrary; some lymphomas that heavily involve the marrow are treated as leukemia. Both are treated primarily with chemotherapy.

At what age do childhood cancers usually appear?

It depends on the type. Neuroblastoma, retinoblastoma, Wilms tumor and hepatoblastoma are diseases of babies and preschoolers, because they grow from tissue left over from fetal development. Acute lymphoblastic leukemia peaks between ages two and five. Bone sarcomas, Hodgkin lymphoma and thyroid cancer cluster in adolescence, often during or after the growth spurt. Brain tumors occur across all childhood ages.

Is childhood cancer hereditary?

Usually not. Large genetic studies find an inherited predisposition in roughly 8 to 10 percent of childhood cancers, including conditions such as hereditary retinoblastoma, Li-Fraumeni syndrome, neurofibromatosis and Down syndrome. The remaining cases arise from random genetic errors during development. Genetic counseling is increasingly offered to families, especially when a child is diagnosed very young, has tumors in both of a paired organ, or has relatives with early cancers.

What are the early warning signs of cancer in a child?

Persistent unexplained fever, pallor and fatigue, bruising in unusual places, a painless growing lump, a swollen belly, morning headaches with vomiting, new balance or vision problems, bone pain in one spot that wakes a child at night, and a white pupil reflection in photographs are the signs clinicians look for. Each is far more often caused by something minor, but persistence or an unusual combination warrants prompt medical assessment.

How long does childhood cancer treatment take?

It ranges widely by type. Acute lymphoblastic leukemia treatment typically lasts two to three years, most of it in a lower-intensity maintenance phase. Acute myeloid leukemia uses shorter but more intense courses over several months. Many solid tumors are treated over roughly six months to a year with chemotherapy, surgery and sometimes radiation. The child’s oncology team sets the schedule based on subtype and response.

Can childhood cancer be prevented?

For the most part, no. Unlike many adult cancers, childhood cancers are not linked to diet, lifestyle or common environmental exposures, so there is no proven prevention strategy for the general population. Exceptions are narrow: children with known genetic predisposition syndromes are offered surveillance to catch tumors early, and avoiding unnecessary high-dose radiation is sensible. Early recognition and complete treatment are what the evidence shows improve outcomes.

References

• Childhood cancer fact sheet (WHO)
• Cancer in Children (MedlinePlus)
• Acute lymphoblastic leukaemia (NHS)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.